Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,296 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05766098Recruiting
Genetic testing of papillary thyroid tumor samples
This trial studies the genetic “mutations” in papillary thyroid cancer tumors using tumor tissue. The goal is to better describe tumor genetic patterns, which may help researchers understand the disease.
Milan, MIAges Any age - NCT07723482RecruitingPhase 1/Phase 2
Study of ML-016 for cancer that has spread to lungs or liver
This trial tests a new drug called ML-016 in people whose advanced cancer has spread to their lungs or liver and who have run out of standard treatment options. The goal is to see if ML-016 can shrink tumors or slow the cancer's growth.
Miranda, New South WalesAges 18 years+ - NCT07717242RecruitingPhase 2
Bladder cancer study testing a new drug combination before surgery
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
Guangzhou, GuangdongAges 18 years+ - NCT07708935Recruiting
Study of young patients with solid tumors in China
This study looks at young people (40 or younger at diagnosis) with solid tumors in China. It aims to collect real-world information about their treatments and outcomes to find patterns that could help improve care.
ShanghaiAges 18–80 - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT07693283Recruiting
Markers in endometriosis tissue
This study looks at certain markers (proteins) in endometriosis tissue to better understand the condition. It may help find new ways to diagnose or treat endometriosis in the future.
Beijing, Beijing MunicipalityAges 18–50 - NCT07678957RecruitingPhase 2
Comparing BL-M07D1 vs DS-8201 for HR-positive, HER2-low breast cancer
This trial compares a new drug, BL-M07D1, to an existing treatment (DS-8201) for women with HR-positive, HER2-low breast cancer that has come back or spread. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07667751RecruitingPhase 2
Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
HefeiAges 18–75 - NCT07660432RecruitingPhase 1
Testing SIM0689 for advanced solid tumors
This study tests a new drug called SIM0689 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective, and researchers will look at tumor samples to understand which patients might benefit most.
Fuzhou, FujianAges 18 years+ - NCT07660055RecruitingPhase 1
Radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (called 177Lu-DWJ155) that targets and kills cancer cells, along with a similar imaging agent (68Ga-DWJ155) used to see where the drug goes in the body. It is for people with certain advanced solid tumors that have not responded to standard therapies.
Omaha, NebraskaAges 18 years+ - NCT07656090Enrolling by invitationEarly Phase 1
Testing IDOV-Immune for advanced solid tumors
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07648472RecruitingPhase 1
Safety and efficacy of OVV-01 injection for advanced solid tumors
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07644403Enrolling by invitationPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Solid Tumors
This trial tests IMC001, a new type of immune cell therapy designed to fight advanced solid cancers that have stopped responding to standard treatments. The therapy uses your own immune cells engineered to recognize and attack cancer cells.
BeijingAges 18–75 - NCT06003621RecruitingPhase 2
Tiragolumab and atezolizumab for advanced solid tumors
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
Albury, New South WalesAges 18 years+ - NCT07645469RecruitingPhase 1
WT1-targeting T cells with azacitidine for AML
This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) that has minimal residual disease (small amounts of cancer left after treatment). The therapy uses your own immune cells, modified to target a protein called WT1 on leukemia cells, and combines it with a drug called azacitidine.
Seattle, WashingtonAges 18 years+ - NCT06269211RecruitingPhase 2
Immunotherapy before surgery for EGFR-mutated lung cancer
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
Guangzhou, GuangdongAges 18 years+ - NCT03971045RecruitingPhase 2
Pembrolizumab plus low-dose oral chemo for chest wall breast cancer
This Phase 2 trial tests pembrolizumab (an immune therapy) plus low-dose oral cyclophosphamide in people with chest wall breast cancer that has spread locally and may have distant metastases. It aims to see if this combination can shrink tumors and control cancer longer, especially in tumors with certain immune markers.
MilanAges 18 years+ - NCT07631793RecruitingPhase 1
Experimental vaccine for advanced solid tumors
This trial tests an experimental vaccine called YKYY031 for people with advanced solid tumors that have stopped responding to standard treatments. The vaccine aims to help your immune system fight cancer cells that carry specific markers. It may be an option if you have certain genetic markers and tumor proteins.
Beijing, Beijing MunicipalityAges 18–75 - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT07623850RecruitingPhase 1
Early Study of JLM019 Injection for Advanced Cancers
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07622940RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Esophageal Cancer
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07623265Recruiting
Understanding Immunotherapy Response in Liver Cancer
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
AntwerpAges 18 years+
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,296 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.